FAIR LAWN, N.J.--(BUSINESS WIRE)--Vyteris, Inc. (OTC BB: VYTR), manufacturer of the first FDA-approved active patch transdermal drug delivery system, received $2.5 million principal amount of financing effective on July 9, 2008 from Ferring Pharmaceuticals, Inc. (“Ferring”), which represented an advance on a potential milestone payment for a Phase II clinical trial of a product for female fertility treatment.
